Product Name: Ledipasvir (GS-5885)
Synonyms: GS 5885; GS5885; GS-5885; Ledipasvir; GS-5885/Ledipasvir; gs-5885/gs5885; Ledipasvir / GS 5885; GS 588
CAS: 1256388-51-8
MF: C49H54F2N8O6
Molecular Weight: 889.0
Product Categories: API
Categories: NS5A inhibitors; Fluorenes; Carbamates; Benzimidazoles; Cyclopropanes; Imidazoles; Breakthrough therapy
Purity : 98%
Solubility DMSO
Storage at -20°C
Appearance : White powders
Package : 50g/foil bag
Usage : Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. This drug has been tested and shown efficacy in treatment-naive and treatment experienced patients.

Product Description :


Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U. S. Approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.

Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1. The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.

On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg called Harvoni.

Application :

GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype 1 HCV replicons. GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with> 95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Ledipasvir (formerly GS-5885) is currently in Phase III clinical trials.


Pharmaceutical Intermediates

Dexamethasone CAS: 50-02-2
Dutasteride CAS: 164656-23-9
Finasteride CAS: 98319-26-7
Formestane CAS: 566-48-3
Cabergoline CAS: 81409-90-7
Paclitaxel CAS: 33069-62-4
Phenacetin CAS: 62-44-2
Paracetamol CAS: 103-90-2
GBL/Gamma-Butyrolactone CAS: 96-48-0
BA/Benzyl alcohol CAS: 100-51-6
BB/Benzyl benzoate CAS: 120-51-4
Grape seed oil CAS: 85594-37-2
ETHYL OLEATE CAS: 111-62-6


SARMs

MK-2866 CAS: 1202044-20-9, 841205-47-8
LGD-4033 CAS: 1165910-22-4
GW-501516 CAS: 317318-70-0
MK-677 CAS: 159752-10-0
GTX-007/S4/Andarine CAS: 401900-40-1
SR-9009 CAS: 1379686-30-2
RAD-140 CAS: 118237-47-0
YK-11 CAS: 431579-34-9
GW0742 CAS: 317318-84-6
AICAR CAS: 2627-69-2
GS5816 CAS: 1377049-84-7


Hot selling market :

United State(USA) , United Kingdom(UK) , Australia , Canada , Spain , France , Germany , Russia , Brasil(Brazil) , Ukraine , South Africa , Norway , Poland , Netherlands(Holland) , Slovakia , Georgia , New Zealand , Sweden etc.